Timothy Lu

Synthetic Biologist | Biotech Entrepreneur | MIT Professor

[Senti Biosciences @SentiBio]

Dr. Kanya Rajangam, Chief Medical Officer, emphasized that the encouraging SENTI-202 data support advancement into pivotal studies and exploration across additional patient populations, enabled by recent RMAT and Orphan Drug Designations.

https://t.co/T4H28dd2Ee

$SNTI #ASH2025

[Timothy Lu @timlu]

Thanks to Dr. Farhad Ravandi from @MDAndersonNews for sharing thoughts on the potential for $SNTI's SENTI-202 product to transform the treatment of AML and other cancers. Published by @VJHemOnc https://t.co/t2uZXgfLNu

[Timothy Lu @timlu]

Thanks to @GeneOnlineNews for highlighting @SentiBio 's recent SENTI-202 data for R/R AML @ ASH. With 50% ORR, RMAT designation, favorable safety, off-the-shelf delivery, we hope to advance this program quickly into pivotal studies for patients in need

https://t.co/h92zhJvmJe

[Timothy Lu @timlu]

$SNTI recently reported our Logic Gated SENTI-202 cell therapy achieved 50% ORR, 42% CR/CRh, 7.6 month cCR durability in heavily pretreated refractory/refractory AML patients at #ASH25. This is an exciting new treatment modality for R/R AML, a disease with a median OS ~5 months

[Senti Biosciences @SentiBio]

Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep, durable responses and a favorable safety profile in R/R AML, underscoring its potential to selectively target AML cells while preserving healthy ones.

https://t.co/T4H28dd2Ee
$SNTI #AML #ASH2025

[Timothy Lu @timlu]

@drpatrick @BillOReilly @drpatrick I agree with the power of NK cells. @SentiBio just presented exciting data at #ASH2025 showing that SENTI-202 Logic Gated CAR-NK cells are able to generate deep, durable responses in relapsed/refractory AML with a well tolerated safety profile

[Senti Biosciences @SentiBio]

If you missed our CEO, Tim Lu, at the H.C. Wainwright 27th Annual Global Investment Conference, don’t worry — you can watch the full presentation now!

🎥 Replay available here: https://t.co/QwmYmwmNzN

$SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia

[Timothy Lu @timlu]

@AACR @SarahCannonDocs Thank you to Dr. Strickland for presenting @SentiBio's SENTI-202 program at #AACR25 yesterday. We're excited to continue advancing our Logic Gated cell therapies for difficult cancers! $SNTI

[Timothy Lu @timlu]

Excited to share updates on Senti Bio’s SENTI-202 program with Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML. Come join us at 830 AM ET webinar! $SNTI https://t.co/HJAXWnsVDs

[Timothy Lu @timlu]

@jortiz81 Awesome!

[Senti Biosciences @SentiBio]

Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025

https://t.co/1p4qnMjopA
@AACR

[Senti Biosciences @SentiBio]

#MarkYourCalendars: $SNTI leadership will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at #AACR2025 on Monday, April 28, 2025, at 8:30 AM ET. Access it here: https://t.co/QZ7Q8NUpBJ

#CellTherapy #CARNK #AML @AACR

[Senti Biosciences @SentiBio]

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

https://t.co/1p4qnMjopA
$SNTI #CellTherapy #CARNK @AACR #AACR25

[Timothy Lu @timlu]

Excited to share the latest clinical and preclinical data on our Logic Gated SENTI-202 product at the upcoming AACR meeting!

[Senti Biosciences @SentiBio]

Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025

https://t.co/1p4qnMjopA
@AACR

[Timothy Lu @timlu]

Very excited to share details on SENTI-202 clinical trial - 2 of 3 pts achieved MRD negative CR in 1st dose level evaluated with a generally well-tolerated preliminary safety profile. Both patients continue to maintain remission (4+ and 3+ months, respectively). $SNTI

[Senti Biosciences @SentiBio]

Today, we announced positive initial clinical data from the Phase 1 trial of SENTI-202, a potential first-in-class, off-the-shelf #CARNK #celltherapy for R/R hematologic malignancies, including #AML. Learn more on our webcast on Dec. 3 at 7:30am ET: https://t.co/rM1ybrtfQ0 $SNTI

[Timothy Lu @timlu]

Excited to share the detailed data on SENTI-202 with Dr. Stephen Strickland and Dr. Kanya Rajangam. Join us to learn about how our #genecircuits enhanced CAR-NK therapies have the potential to transform the treatment of cancer through Logic Gating. $SNTI

[Senti Biosciences @SentiBio]

Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: https://t.co/rM1ybrtfQ0 $SNTI

[Senti Biosciences @SentiBio]

Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: https://t.co/rM1ybrtfQ0 $SNTI

[Timothy Lu @timlu]

Congratulations to @SentiBio for its $8M award from California Institute for Regenerative Medicine (CIRM) for its Logic-Gated SENTI-202 clinical trial for relapsed/refractory AML. Thanks so much to CIRM for this support! $SNTI

https://t.co/jM0bBtDEsU

[Amir Shanehsazzadeh @amirshanehsaz]

We @abscibio are excited to unveil IgDesign™ @NeurIPSConf and present our work at @workshopmlsb @AI4D3 @genbio_workshop! IgDesign is an antibody inverse folding model that we have experimentally validated in our lab. Read the paper here: https://t.co/H5xDtNt0NE #NeurIPS2023

[Timothy Lu @timlu]

Check out how $SNTI's Logic Gates precisely discriminate between cancer cells and healthy cells, allowing us to achieve highly precise cancer therapeutics! #synbio

[Senti Biosciences @SentiBio]

At Senti, we envision a world where #cancer patients can access smarter therapies that precisely kill their cancer cells and spare their healthy cells. Watch to learn how we're utilizing our proprietary Logic Gating technology to design #CARNK cell therapies to achieve this goal.

[Timothy Lu @timlu]

Exciting times for @SentiBio as we gain extra fuel to power our Gene Circuit enhanced cell therapies to patients.

[Senti Biosciences @SentiBio]

Today, we announced that Celadon Partners will acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies. Learn more: https://t.co/F4LJvTCMqz